Cancer treatment
AssigneePropanc Pty Ltd
InventorsMacarena Perán Quesada, Julian Kenyon, Juan Antonio Marchal Corrales, Maria Angel Garcia Chaves
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, methods, uses and kits for treating cancer. The present invention relates to methods for minimising the progression of cancer in a subject, the method comprising administering to the subject therapeutically effective amounts of chymotrypsinogen and trypsinogen, thereby minimising the progression of cancer in the subject. In particular, the methods provide a means for treating cancer by reducing the number of cancer stem cells in the subject.
Claims12
A method of minimising the progression of cancer in a subject who has received a treatment for cancer, wherein the method comprises:
- detecting the presence of cancer stem cells in the subject by identifying cells expressing one or more cancer stem cell markers, wherein the cancer stem cell markers comprise:
- CD34+, CD38−, CD71−, CD90−, C117−, CD123+;
- or ESA+, CD44+, CD24−, ALDH-1 or CD133+CD49f+, CD90+;
- or CD133+, BCRP1+, A2B5+, SSEA-1+;
- or CD133+, ABCG2:
- or CD133+, CD44+, CD166+, EpCAM+, CD24+, CD326+, C D44+;
- or CD138−;
- or CD44+, α2β1, CD 133+;
- or CD133+, CD44+, EnCAM+, CD24+, CD326+, CD44+, CxCr4+;
- or CD20+, or CD144+;
- and
- wherein when the subject is determined to have cancer stem cells, administering to the subject, therapeutically effective amounts of chymotrypsinogen and trypsinogen, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.
Dependencies are inferred from the claim text.